Trial news: The AGITG currently has eleven studies open to recruitment and four studies in follow up.
The table below details the trials that are currently accruing patients.
| Recruited | Target | |
| ACTICCA-1- Gallbladder carcinoma | 3 | 50 |
| ASCOLT — Colorectal cancer | 299 | 400 |
| CONTROL NETs — NeuroEndocrine Tumour | 70 | 75 |
| DYNAMIC-III | 48 | 1000 |
| DYNAMIC-Rectal | 2 | 408 |
| INTEGRATE II – Gastro-Oesophageal | 33 | 90 |
| LIBERATE | 17 | 100 |
| MONARCC | 1 | 80 |
| NABNEC | 22 | 70 |
| SPAR | 2 | 222 |
| TOP GEAR – Stomach cancer | 199 | 280 |
Trial Results Lay Summaries (click on the links below):Recruitment figures to end July 2018.
ALaCaRT
ATTACHE
ATTAX-3
GAP
ICECREAM
INTEGRATE
TACTIC
TOP GEAR
CO.17
EORTC 62024
Advanced GIST